腹腔热灌注化疗对卵巢癌患者血清miR-200a的影响

目的：探讨腹腔热灌注化疗对卵巢癌患者血清miR-200a的影响。方法：将82例手术治疗后的卵巢癌患者随机分为两组，观察组与对照组各41例。观察组采用全身静脉化疗联合腹腔热灌注化疗，对照组采用全身静脉化疗联合普通腹腔灌注化疗。治疗3个疗程后观察疗效，并且测定患者血清miR-200a。结果：观察组总有效率为87．8％，对照组总有效率为73．2％，两组差异有统计学意义（P〈0．05）。治疗后两组患者血清miR-200a均有明显降低，观察组降低更加明显（P〈0．05）。结论：腹腔热灌注化疗对卵巢癌的效果更明显，可能与减少miR-200a的表达有关系。

Effect of intraperitoneal hyperthermic perfusion chemotherapy on serum miR-200a in patients with ovarian cancer

Objective： To study the effect of intraperitoneal hyperthermic perfusion chemotherapy on serum miR- 200a in patients with ovarian cancer. Methods： Eight-two patients with ovarian cancer after operation were randomly divided into two groups, the observation group（ n = 41 ） and the control group （n = 41 ）. The patients in the observation group were treated through intravenous plus intraperitoneal hyperthermic perfusion chemotherapy, while the patients in the control group were treated through intravenous plus intraperitoneal perfusion chemotherapy. They were all treated for three courses. The level of serum miR-200a in two groups was detected. Results： The total efficient rates were 87.8% in the observation group and 73.2% in the control group. There was a significant difference between two groups （P 〈 0.05 ）. The level of serum miR-200a in both groups was decreased after chemotherapy and it was lower in the observation group than that in the control group （ P 〈 0.05 ）. Conclusion： Hyperthermic perfusion chemotherapy can decrease miR-200a which can improve ovarian cancer.